Short Interest in LifeVantage Co. (NASDAQ:LFVN) Drops By 16.1%

LifeVantage Co. (NASDAQ:LFVNGet Rating) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 40,500 shares, a decline of 16.1% from the March 31st total of 48,300 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 49,400 shares, the days-to-cover ratio is currently 0.8 days.

In related news, Director Michael A. Beindorff acquired 7,193 shares of the stock in a transaction dated Monday, February 7th. The shares were bought at an average cost of $4.85 per share, for a total transaction of $34,886.05. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 5.52% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC bought a new position in LifeVantage in the fourth quarter valued at about $63,000. Victory Capital Management Inc. boosted its stake in shares of LifeVantage by 39.0% in the 4th quarter. Victory Capital Management Inc. now owns 10,633 shares of the company’s stock valued at $67,000 after purchasing an additional 2,983 shares during the last quarter. O Shaughnessy Asset Management LLC grew its position in shares of LifeVantage by 544.6% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,657 shares of the company’s stock worth $106,000 after buying an additional 13,228 shares during the period. Two Sigma Advisers LP raised its stake in shares of LifeVantage by 16.0% during the third quarter. Two Sigma Advisers LP now owns 18,900 shares of the company’s stock worth $128,000 after buying an additional 2,600 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in LifeVantage by 10.4% in the second quarter. Bank of America Corp DE now owns 26,146 shares of the company’s stock valued at $192,000 after buying an additional 2,467 shares during the period. Institutional investors own 29.54% of the company’s stock.

Separately, began coverage on shares of LifeVantage in a report on Thursday, April 28th. They set a “buy” rating for the company.

LifeVantage stock opened at $4.18 on Wednesday. The stock has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $5.85. The stock has a market capitalization of $53.72 million, a price-to-earnings ratio of 5.73 and a beta of 1.39. LifeVantage has a 12-month low of $3.87 and a 12-month high of $8.66.

LifeVantage (NASDAQ:LFVNGet Rating) last announced its earnings results on Tuesday, May 3rd. The company reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.01. LifeVantage had a net margin of 4.73% and a return on equity of 30.05%. During the same period in the prior year, the firm earned $0.20 earnings per share. Equities analysts predict that LifeVantage will post 0.69 EPS for the current fiscal year.

LifeVantage Company Profile (Get Rating)

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes.

Featured Stories

Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with's FREE daily email newsletter.